View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 26, 2016updated 13 Jul 2022 10:13am

GamaMabs doses first patient in Phase Ia/Ib study of GM102 to treat advanced gynecological cancer

French-based biotechnology company GamaMabs Pharma has dosed the first patient in the Phase Ia/Ib study of GM102 to treat advanced gynecological cancer.

French-based biotechnology company GamaMabs Pharma has dosed the first patient in the Phase Ia/Ib study of GM102 to treat advanced gynecological cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

GM102 is a first-in-class, monoclonal antibody (mAb) targeting the anti-Müllerian human receptor II (AMHR2 / MISR2) characterising gynecological cancers.

It is based on the EMABling glyco-engineering technology, which activates its immune system cells to kill the tumour cells.

The company noted that the first administration of GM102 has taken place at the Jules Bordet Institute in Brussels, Belgium, with AMHR2-positive patients suffering from advanced pre-treated gynecological cancer.

"We are extremely pleased with the accrual rate at Jules Bordet, to which French centres will be soon aggregated."

The trial is primarily focused to evaluate the safety in the administration of GM102 and to determine a dose for future Phase Ib/II trials.

GamaMabs Pharma research and development vice-president Jean-François Prost said: “As this is the very first time an AMHR2-targeting drug is being tested in oncology patients, we are very excited about generating data that can guide us through the development of GM102 in Phase II.

“We are extremely pleased with the accrual rate at Jules Bordet, to which French centres will be soon aggregated.”

According to principal investigator of the study at the Jules Bordet Institute Ahmad Awada, the mechanism of GM102 can be leveraged to treat gynecological cancers, namely ovarian, endometrium and cervical, and can also improve the treatment of relapsing patients.

The first stage of the Phase Ia/Ib dose escalation study is expected to be completed by next year, following which the company is planning to commence the second stage of the study consisting of two expansion cohorts in gynecological cancers.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena